Table 4.
Subsequent medication use following index acromegaly-related medication
| Subsequent medication, n (%) | Index medication | |||||
|---|---|---|---|---|---|---|
| Octreotide ACE (N = 103) |
Octreotide LAR (N = 49) |
Lanreotide (N = 11) |
Pegvisomant (N = 17) |
Bromocriptine (N = 26) |
Cabergoline (N = 57) |
|
| Octreotide acetate (ACE) | – | 3 (6.1) | 0 (0.0) | 3 (17.6) | 4 (15.4) | 15 (26.3) |
| Octreotide LAR | 54 (52.4) | – | 1 (9.1) | 3 (17.6) | 1 (3.8) | 11 (19.3) |
| Lanreotide | 3 (2.9) | 4 (8.2) | – | 0 (0.0) | 0 (0.0) | 3 (5.3) |
| Pegvisomant | 17 (16.5) | 3 (6.1) | 2 (18.2) | – | 1 (3.8) | 5 (8.8) |
| Bromocriptine | 4 (3.9) | 1 (2.0) | 0 (0.0) | 0 (0.0) | – | 1 (1.8) |
| Cabergoline | 17 (16.5) | 5 (10.2) | 1 (9.1) | 2 (11.8) | 4 (15.4) | – |